Articles |
From the Division of Clinical Pharmacology, Department of Medicine and Therapeutics, Leicester Royal Infirmary, United Kingdom.
Correspondence to Dr Martin Siczkowski, Division of Clinical Pharmacology, Department of Medicine and Therapeutics, Clinical Sciences Bldg, Leicester Royal Infirmary, Leicester, LE2 7LX, UK.
| Abstract |
|---|
|
|
|---|
Key Words: Na+-H+ antiport hypertension vascular smooth muscle cells phosphorylation
| Introduction |
|---|
|
|
|---|
Since the cloning of the ubiquitous growth factorsensitive NHE isoform 1 (NHE-1) by Sardet et al,14 other isoforms of the NHE (NHE-2, NHE-3, and NHE-4) have been recently described in tissues, such as gut and kidney, in which there is transepithelial Na+ transport.15 16 17 Most of the reports on NHE activity in hypertension have used cells expressing mainly NHE-1 rather than the other isoforms.1 The reason for the increased activity of NHE-1 in SHR is at present unknown, although we have recently reported that the increased activity of Na+-H+ exchange in SHR vascular and striated myocytes was not due to an increased number of NHE-1 transporters but to an increased turnover number at each site.18 Posttranslational processes such as phosphorylation19 and N-linked glycosylation20 are known to affect NHE activity. However, the similarities in the molecular weight of NHE-1 from SHR and WKY tissue extracts make gross differences in N-linked glycosylation between the strains unlikely.18 We therefore used NHE-1specific polyclonal antibodies to determine whether the differences in Na+-H+ exchange in SHR and WKY vascular myocytes were associated with differences in NHE-1 phosphorylation and whether SHR cells were more responsive to stimulation with FCS. Our findings suggest that NHE-1 from quiescent SHR vascular myocytes is more heavily phosphorylated than that from WKY myocytes and that FCS may stimulate Na+-H+ exchange in both cell types without any further increase in total NHE-1 phosphorylation.
| Materials and Methods |
|---|
|
|
|---|
Cell Culture and Measurement of NHE Activity
SHR and WKY rats were obtained from the colony maintained at the
Biomedical Services Unit, Leicester University. The blood pressure
(mean±SD) of 12-week-old rats, measured by the tail-cuff method, was
171±11 mm Hg in SHR and 118±7 mm Hg in WKY rats. These rats were
then anesthetized with pentobarbital sodium (50 mg/kg IP), and the
thoracic aorta was rapidly dissected free of adventitia. Vascular
myocyte lines were obtained from aortic explants, as described
previously,8 and cultured in Ham's F-12 growth medium.
Cultures were studied between passage numbers 5 and 14. NHE activity
was measured in SHR and WKY vascular myocytes seeded onto glass
coverslips, as described previously,7 8 18 and were
cultured for 4 days before study. When the cells were confluent, they
were rendered quiescent by serum deprivation for 24 hours in DMEM
containing 1 g/L bovine serum albumin (BSA), 2 mmol/L glutamine, and
antibiotics. Cells adherent on the coverslips were loaded with 5
µmol/L BCECF-AM for 30 minutes in serum-free DMEM at 37°C, washed
twice, and then left at room temperature for a further 30 minutes to
deesterify the dye. For measurement of the resting
pHi, the coverslips were clamped at an angle of
60° to the incident light in a quartz cuvette containing HBSS
composed of (mmol/L) NaCl 130, KCl 5, CaCl2 1.8,
MgSO4 1, glucose 5, and HEPES 20, along with BSA at 1 g/L,
pH 7.4, in a 37°C thermostatted sample compartment holder within a
dual grating fluorometer (Delta- scan, Photon Technology International
Inc), which had dual-wavelength excitation (500 and 439 nm; slit
widths, 5 nm) and emission at 530 nm (slit width, 5 nm). The 500/439
ratios were calibrated using nigericin and monensin (5 µmol/L each)
in isotonic KCl buffers (replacing the NaCl of HBSS with KCl and
omitting the BSA) having various pH values in the range of 6.0 to 8.0,
as previously described.8 The pHi was clamped
to 6.0 (near the Vmax of the Na+-H+
antiporter8 ) by incubation of the cells in isotonic KCl
buffer (pH 6.0) containing 5 µmol/L monensin and 5 µmol/L nigericin
for 5 minutes at 37°C. The ionophores were then scavenged by addition
of BSA. The passive rate of change of pHi
(dpHi/dt) was measured by addition of
Na+-free medium (replacing the NaCl in HBSS with
N-methyl-D-glucamine chloride, pH
7.4). The total dpHi/dt was determined in HBSS, and
the Na+-dependent dpHi/dt was calculated
as the difference between total and passive measurements. The
dpHi/dt values were computed from linear regression
of the first 20 seconds of recordings after addition of
Na+-free or Na+-containing buffers, using
100 readings from the recordings (each reading averaged >200
milliseconds). Pearson correlation coefficients always exceeded 0.99
for these regressions. Intrinsic buffering capacity was measured after
addition of an NH4Cl pulse (final concentration, 50
mmol/L), and fluxes mediated by NHE at pHi 6.0 were
calculated by the product of buffering capacity and the
Na+-dependent dpHi/dt.8 All
flux measurements reported were performed on cells after clamping of
pHi to 6.0. Readings were made on cells in the absence of
serum and then repeated on similar coverslips after 20 minutes of
incubation with 10% FCS at 37°C. These matched experiments in the
absence or presence of serum were performed within 30 minutes of each
other and in random order.
Production of Polyclonal Antibodies to Human NHE-1
Polyclonal antibodies were raised to the regulatory C-terminus
of NHE-1 by using a fusion protein consisting of ß-galactosidase and
amino acids 658 to 815 of NHE-1. These nucleotides had been inserted
into a PEX 3 vector (EMBL, Genofit), which was a gift from Prof J.
Pouyssegur and Dr C. Sardet (University of Nice,
France).19 Induction of the ß-galactosidaseNHE-1
C-terminal fusion protein was by incubation of the bacteria at 42°C
for 2 hours as previously described.19 After two
separations on SDS-PAGE, the ß-galactosidase fusion protein was
electroeluted from gel slices. Over a period of 6 months, two rabbits
were immunized with monthly intravenous injections of 100 µg of the
ß-galactosidase fusion protein. The NHE-1specific immunoglobulin
was purified from polyclonal sera of each rabbit by elution from
protein ASepharose CL4B beads. Antibody G252 was used in Western
blots to detect and quantify the amount of NHE-1 present in
vascular myocyte extracts,18 and antibody G253 was used in
the immunoprecipitation experiments that are described below.
Another fusion protein was constructed where the nucleotides representing the above amino acids of NHE-1 were inserted into the Sma I and EcoRI sites of a pGEX-2T plasmid. This led to the production of a glutathione S-transferaseNHE-1 C-terminal fusion protein (GST fusion protein) that had a C-terminal amino acid sequence identical to that of the C-terminus of the ß-galactosidaseNHE-1 fusion protein that had been used to raise the antibodies (G252 and G253). Induction of GST fusion protein production was with 1 mmol/L isopropyl ß-D-galactopyranoside. This fusion protein was purified on a glutathioneSepharose 4B column and eluted with addition of 5 mmol/L glutathione. Thus, the antibodies used in our studies reacted only with the NHE-1 C-terminus of this fusion protein, and the fusion protein could be used to check specificity of antibody reactions on Western blots.
Determination of NHE-1 Density by Western Blotting
We measured the NHE-1 contents of cultures from SHR and
WKY myocytes by performing Western blots of these extracts, using a
previously described method.18 This was to ensure that
phosphorylation was measured on identical numbers of NHE-1 transporters
in the two different strains. In brief, cells were snap-frozen with
liquid nitrogen and scraped off the tissue culture flasks into a buffer
containing (mmol/L) Tris 50, pH 7.4, NaCl 140, EDTA 5,
phenylmethylsulfonyl fluoride 1, o-phenanthroline 1, and
iodoacetamide 1. An equal volume of buffer containing 125 mmol/L Tris,
pH 6.8, 4% SDS, 20% glycerol, and 0.004% bromophenol blue was added,
and the mixture was then boiled for 3 minutes. Extracts were resolved
on 7.5% SDS-PAGE gels and electrotransferred onto supported
nitrocellulose. Blocking of these membranes overnight with 10% low-fat
milk powder (Marvel) in 20 mmol/L Tris, pH 7.4, 137 mmol/L NaCl, and
0.1% Tween 20 (TBS-Tween) was followed by addition of 1 µg/mL G252
antibody in 5% Marvel in TBS-Tween for 2.5 hours. After seven washes
in TBS-Tween, horseradish peroxidaselinked donkey anti-rabbit second
antibody (1:1500 dilution) was incubated with the membranes for 1 hour,
after which detection using enhanced chemiluminescence (Amersham) was
performed. The bands corresponding to NHE-1 (molecular weight,
95
kD) were quantified on a Bio-Rad densitometer.18 The
reactivity of antibodies with this band was completely abolished by the
inclusion of 2 µg/mL GST fusion protein to neutralize the components
of the serum reactive against the C-terminus of NHE-1.
Determination of NHE-1 Phosphorylation
Phosphorylation of NHE-1 was measured in quiescent
vascular myocyte cultures by incubating the cells in
[32P]orthophosphate (50 µCi/mL) for 3 hours in
phosphate-free HBSS composed of (mmol/L) NaCl 130, KCl 5,
CaCl2 1.8, MgSO4 1, glucose 5, HEPES 20, and
glutamine 2, along with BSA at 1 g/L, pH 7.4. The method for
immunoprecipitation was adapted from that of Sardet et
al.19 Cells that had been labeled were washed briefly with
cold HBSS and snap-frozen with liquid nitrogen. One milliliter of cold
(4°C) extraction buffer (containing 10 g/L polyoxyethylene-8-lauryl
ether, 30 mmol/L Tris, 130 mmol/L NaCl, 5 mmol/L EDTA, 1 mmol/L
phenylmethylsulfonyl fluoride, 1 mmol/L
o-phenanthroline, 1 mmol/L iodoacetamide, 100 mmol/L
sodium fluoride, 5 mmol/L sodium orthovanadate, 10 mmol/L ATP, 10
mmol/L sodium pyrophosphate, 1 mg/L pepstatin A, and 2 mg/L leupeptin)
was then added to the frozen cells, and the monolayers were scraped off
the plastic flasks. After sonication, cell debris was removed by
centrifugation at 14 000g. The supernatant was then
preabsorbed with protein ASepharose CL4B beads, and the samples were
recentrifuged. The antibody G253 was then added to the supernatant at a
final concentration of 100 µg/mL, and the samples were rotated end on
end for 2 hours at 4°C. Protein ASepharose-CL4B beads that had been
pretreated with unlabeled vascular myocyte cell extracts to reduce
nonspecific binding were then added for 1 more hour. The beads were
washed extensively in extraction buffer containing 1 g/L ovalbumin
before solubilization in Laemmli sample buffer for SDS-PAGE
analysis on 7.5% gels. Phosphoproteins were detected by
autoradiography on preflashed x-ray films. The densities of the
32P-labeled NHE-1 were determined with a Bio-Rad
densitometer and associated software. Readings were automatically
corrected for the background density of the same track by using troughs
in the density profile adjacent to the NHE-1 band. Values were
normalized to an arbitrary value of 1 for the quiescent WKY cell
extract.
The effect of FCS on NHE-1 phosphorylation was then investigated by incubating quiescent 32P-prelabeled myocyte cultures in HBSS containing 10% FCS for periods of up to 20 minutes at 37°C. The phosphate in the FCS had been effectively removed by gel filtration, using Sephadex G25, into buffer containing (mmol/L) NaCl 140, KCl 5, and HEPES 30, pH 7.4.
To ensure that we could detect any increase in NHE-1 phosphorylation, we performed two sets of positive controls. In the first positive control, the effect of serum on NHE-1 phosphorylation was investigated by using human lymphoblasts cultured in RPMI 1640 growth medium containing 10% FCS. Cells (1.5x107) were rendered quiescent by 24-hour serum withdrawal, being incubated with RPMI 1640 medium containing 1 g/L BSA. The cells were then washed three times in phosphate-free HBSS and resuspended in 1 mL HBSS, with the pH adjusted to 7.4 with NaOH. Addition of 2 MBq carrier-free [32P]orthophosphate to the 1-mL cell suspension was followed by incubation for 3 hours at 37°C. The cells were recovered and split into two aliquots. One was resuspended in HBSS, and the other was treated with 10% FCS in HBSS for 20 minutes. The second positive control involved studying the effect of arginine vasopressin on NHE-induced cellular alkalinization21 and NHE-1 phosphorylation of SHR and WKY myocytes. SHR cells have been reported to respond to arginine vasopressin with a greater intracellular alkalinization than WKY cells, a finding that may be related to the greater number of V1 receptors.21 Quiescent cells on coverslips were labeled with BCECF-AM, and a baseline pHi was determined in HBSS (37°C) as described above. NHE activity was stimulated with 100 nmol/L arginine vasopressin, and the change in pHi was recorded after 20 minutes. NHE-1 phosphorylation was measured in quiescent SHR or WKY cells prelabeled with [32P]orthophosphate, as described above, and another flask of cells was then stimulated with the 100 nmol/L arginine vasopressin for 20 minutes. After snap-freezing with liquid nitrogen, the protocol for immunoprecipitating NHE-1 and detection by autoradiography was as described above.
Measurement of Specific Activity of Intracellular
[32P]ATP
To examine whether the difference in NHE-1 phosphorylation
between SHR and WKY cultures was due to a difference in the specific
activity of intracellular [32P]ATP, the level of this
compound was determined in cell extracts. SHR and WKY myocytes were
labeled with 250 nCi/mL carrier-free [32P]orthophosphate
for 3 hours and snap-frozen with liquid nitrogen. The frozen monolayers
were scraped into 1 mL cold 10 mmol/L Tris, pH 7.4, containing 5 mmol/L
EDTA. Samples were then centrifuged at 13 000g for 10
minutes. The ATP specific activity was measured by high-performance
liquid chromatography using a 10SAX Partisil anion exchange column. A
linear gradient of 0% to 67% 1.4 mol/L ammonium dihydrogen
orthophosphate was used to elute the ATP. Total ATP levels were
determined by absorption at 254 nm with reference to known ATP
standards. These chromatography peaks were collected, and
32P incorporation into ATP was measured by Cerenkov
counting of these fractions.
Statistics
Results are expressed as mean±SEM, and comparisons were by
Student's t test, performed on an OXSTAT
statistics package (Microsoft Corporation). Two-tailed
P<.05 was considered significant.
| Results |
|---|
|
|
|---|
|
Cells were prelabeled with [32P]orthophosphate as
described above. Incubation of these extracts with the antibody G253
and subsequently with protein ASepharose beads led to
immunoprecipitation of a number of phosphoproteins (Fig 2
). A 95-kD band was identified as NHE-1 from previous
reports of the molecular weight of this exchanger17 18 and
from reactivity of this particular band with NHE-1specific antibody
(G252) on Western blots. Moreover, this reactivity on Western blots was
completely abolished by coincubation of the antibody with GST fusion
protein, indicating the specificity of the reaction to NHE-1. In
addition, incubation of cell extracts with a rabbit antibody with no
immunoreactivity toward NHE-1 extracted a number of phosphoproteins,
but no 95-kD 32P-labeled protein was seen in this region of
the gel (Fig 2
). Incubation of GST fusion protein with this antibody
with no reactivity toward NHE-1 before immunoprecipitation of cell
extracts did not alter the phosphoprotein pattern. Both antibodies
immunoprecipitated phosphoproteins in the 190-kD region, and this may
have obscured a minor amount of dimerized NHE-1 that has been recently
reported.22
|
During subsequent immunoprecipitation experiments with
32P-labeled cell extracts, we also confirmed that the NHE-1
content per cell in these extracts showed no differences between SHR
and WKY myocytes to ensure that differences in phosphorylation of NHE-1
could not be due to differences in total NHE-1 content in the cells.
The mean ratio of SHR to WKY NHE-1 content (per cell) amounted to
0.94±0.13 in the Western blotting studies that accompanied the
phosphorylation experiments (n=8). A typical Western blot of the NHE-1
content of SHR and WKY vascular myocytes is illustrated in Fig 3
(left). Fig 3
(right) illustrates the equivalent
phosphorylation experiment in which a higher density of NHE-1
phosphorylation was demonstrable in quiescent SHR compared with WKY
myocytes. The phosphorylation of NHE-1 in quiescent SHR myocytes was
enhanced
2.17±0.06-fold compared with WKY cells
(P<.001, n=8).
|
The time course of any changes in NHE-1 phosphorylation after
stimulation with 10% FCS was studied in both cell types. The data have
been normalized to a value of 1 for the zero time point. In three
separate experiments on WKY cells, incubation with serum led to a
transient reduction in total NHE-1 phosphorylation, which was apparent
after 1 minute and reached a nadir by 5 minutes (0.47±0.05,
P<.01 compared with the zero time point; Fig 4
). NHE-1 phosphorylation then recovered virtually to
control levels by 20 minutes (0.85±0.11, P=NS compared with
the zero time point) (Fig 4
). This transient dephosphorylation of NHE-1
was not seen in serum-stimulated SHR myocytes (mean levels of NHE-1
phosphorylation relative to a value of 1 at the zero time point were
1.02, 0.88, 0.97, 0.83, and 1.08 after 1, 2, 5, 10, and 20 minutes of
incubation with 10% FCS).
|
When cells were incubated with 10% FCS for 20 minutes, NHE-1
phosphorylation was thus not enhanced further in either cell type (Figs
3 [right] and 5), even though there were very
significant elevations in concomitant measurements of pHi
and NHE activity after 20 minutes of serum stimulation (Fig 1
). Thus,
stimulation of NHE activity by serum could be dissociated from
stimulation of total phosphorylation of NHE-1 in these vascular
myocytes. Even after serum stimulation for 20 minutes, the enhanced
NHE-1 phosphorylation in SHR cells compared with their WKY counterparts
(2.47±0.42 compared with 1.12±0.19, P<.01, n=8) was
maintained (Fig 5
).
|
The specific activity of intracellular [32P]ATP was measured in WKY and SHR cells to assess whether changes in labeling efficiency could account for an apparent difference in NHE-1 phosphorylation in quiescent cultures. There were no differences between WKY and SHR [32P]ATP-specific activities (74.6±2.8 Bq/nmol ATP in WKY compared with 68.3±3.7 Bq/nmol ATP in SHR, P=NS, n=4). Thus, the difference in NHE-1 phosphorylation between strains was not the result of altered 32P-labeling efficiency of ATP.
Two positive controls were performed for the serum stimulation of NHE-1
phosphorylation to verify the above results on vascular myocytes.
First, human lymphoblasts that were quiescent after serum withdrawal
for 24 hours showed a basal phosphorylation of NHE-1 (identified as a
100-kD band on the autoradiogram, Fig 6
) that was
enhanced 2.04±0.10-fold (n=3) after a 20-minute incubation with 10%
FCS at 37°C. Second, addition of 100 nmol/L arginine vasopressin to
quiescent SHR myocytes on coverslips led to a significant intracellular
alkalinization (basal pHi, 7.27±0.04, rising to
7.45±0.06 at 20 minutes after stimulation; P<.005, n=5),
confirming a previous report.21 This response was
abolished in the presence of 50 µmol/L ethylisopropylamiloride. In
contrast, the response of WKY cells was smaller and not significant
(basal pHi, 7.15±0.08, rising to 7.21±0.08 at 20
minutes after stimulation; P=NS, n=5). NHE-1 phosphorylation
in the SHR myocytes was elevated to 153±6% of basal values
(P<.01, n=3), in contrast to WKY myocytes, in which no
significant stimulation of NHE-1 phosphorylation was evident
(poststimulation values, 109±14% of basal values; P=NS,
n=3).
|
| Discussion |
|---|
|
|
|---|
Posttranslational processes such as phosphorylation could lead to rapid stimulation of NHE activity, and growth factors such as serum, epidermal growth factor, thrombin, and phorbol esters may increase NHE activity by phosphorylation.19 23 Our finding of an increased phosphorylation of NHE-1 in quiescent SHR myocytes may contribute to the increased NHE activity of these cells compared with WKY myocytes. This increased phosphorylation of NHE-1 was not due to differences in the labeling efficiency of intracellular ATP pools. The persistence of these abnormalities despite culture of cells in vitro supports a role for genetic factors in determining this enhanced phosphorylation and NHE activity. These findings are in agreement with the suggestion of Livne et al3 that the NHE of platelets from human hypertensive patients is likely to be more active because of increased phosphorylation rather than an increased transporter number. Furthermore, although NHE-1 has been excluded as a candidate gene in human hypertension24 and there have been no reports of mutations of NHE-1 in SHR, this does not preclude modulation of NHE activity in hypertension by processes such as phosphorylation.
Incubation of SHR and WKY myocytes with serum led to very significant increases in pHi and enhancement of NHE activity. Previous work has demonstrated that SHR vascular myocytes proliferate more rapidly than WKY cells, and the DNA synthesis and pHi response to serum and growth factors may be enhanced.7 11 12 13 25 In our present studies, although serum increased NHE activity to a greater extent in SHR myocytes than in WKY myocytes, this was not accompanied by any net increase in NHE-1 phosphorylation in either cell type, even after 20 minutes of incubation. Furthermore, treatment of WKY cells with serum led to a transient dephosphorylation of NHE-1 before recovery to prestimulation levels, implying a reduction in kinase or increase in phosphatase activity immediately following stimulation. These findings are in contrast to previous demonstrations that NHE-1 phosphorylation was increased after serum stimulation,19 although the cells used in that study hyperexpressed epidermal growth factor receptors. Other researchers have shown that NHE-1 activation could be dissociated from increased phosphorylation, eg, during osmotic shrinkage,26 cell differentiation, or stimulation with phorbol esters.27 An additional possibility is that phosphorylation at some sites with dephosphorylation at other sites could have led to stimulation of NHE activity without an increase in net phosphorylation. Recent studies with deletion mutants of NHE-1 have demonstrated the importance of mechanisms not dependent on direct NHE-1 phosphorylation that may have a role in stimulation of transporter activity.28 29 When the terminal section of the cytoplasmic tail of NHE-1 (amino acids 636 to 815) that contained the growth factorsensitive phosphorylation sites was deleted, cytoplasmic alkalinization activated by growth factors was approximately halved. Thus, NHE-1 activity may be modified by direct NHE-1 phosphorylation and other nonphosphorylation-dependent regulatory factors. One possibility is that phosphorylation of NHE-1 may affect the interaction of these proposed regulatory factors with the cytoplasmic domain of NHE-1. However, elucidation of the precise role of the elevated total NHE-1 phosphorylation of quiescent SHR myocytes in mediation of the elevated NHE activity would depend on mapping of the differences in phosphorylation between different sites on NHE-1 of the two rat strains. This would enable a site-directed mutagenesis approach to examination of the relation between phosphorylation at selected sites of the regulatory domain of NHE-1 and NHE activity in SHR cells.
The basis for the enhanced phosphorylation of NHE-1 in quiescent SHR cells may depend on a number of possibilities. Protein kinase inhibitors have been demonstrated to reduce aortic tone and blood pressure in SHR,30 and activators of protein kinase C lead to increased contractile response in SHR aortas.31 In addition, NHE activity in vascular myocytes is dependent on calmodulin,32 and there are several putative sites in NHE-1 that are directly phosphorylated by Ca2+/cal- modulindependent protein kinase II,33 although no evidence for direct phosphorylation of the NHE-1 C-terminus with protein kinase C or cAMP-dependent protein kinase A was found.33 The presence of higher concentrations of intracellular Ca2+ in vascular myocytes from SHR, especially in the subplasmalemmal zone,34 may be responsible for elevated protein kinase C or Ca2+/calmodulindependent protein kinase II activity, resulting directly or indirectly in enhanced phosphorylation of NHE-1 in SHR cells. These possibilities remain to be directly tested in this model of hypertension.
In summary, we have provided the first direct evidence that the enhanced activity and turnover number of NHE-1 in SHR cells is associated with increased phosphorylation of NHE-1 rather than a change in the total number of NHE-1 transporters. The mechanism underlying this finding is unknown at present. It is presently unclear whether the increased basal NHE-1 phosphorylation of quiescent SHR cells compared with that in WKY cells is the mechanism leading to enhanced basal transporter activity. Although SHR myocytes exhibit increased responsiveness to FCS with enhanced alkalinization and NHE activity, these changes were not associated with a net increase in NHE-1 phosphorylation, indicating the existence of other regulatory phenomena that may enhance NHE activity.
| Acknowledgments |
|---|
Received May 16, 1994; accepted February 1, 1995.
| References |
|---|
|
|
|---|
2. Ng LL, Fennell DA, Dudley C. Kinetics of the human leucocyte Na+-H+ antiport in essential hypertension. J Hypertens. 1990;8:533-537.[Medline] [Order article via Infotrieve]
3. Livne AA, Aharonovitz O, Paran E. Higher Na+-H+ exchange rate and more alkaline intracellular pH set-point in essential hypertension: effects of protein kinase modulation in platelets. J Hypertens. 1991;9:1013-1019. [Medline] [Order article via Infotrieve]
4. Dudley CRK, Taylor DJ, Ng LL, Kemp GJ, Ratcliffe PJ, Radda GK, Ledingham JGG. Evidence for abnormal Na+/H+ antiport activity detected by phosphorus nuclear magnetic resonance spectroscopy in exercising skeletal muscle of patients with essential hypertension. Clin Sci. 1990;79:491-497. [Medline] [Order article via Infotrieve]
5. Syme PD, Arnolda L, Green Y, Aronson JKA, Grahame-Smith DG, Radda GK. Evidence for increased in vivo Na+/H+ antiporter activity and an altered skeletal muscle contractile response in the spontaneously hypertensive rat. J Hypertens. 1990;8:1027-1036.[Medline] [Order article via Infotrieve]
6. Kemp GJ, Thompson CH, Radda GK. Proton efflux from rat skeletal muscle in-vivo: changes in hypertension. Clin Sci. 1992;82:489-491. [Medline] [Order article via Infotrieve]
7. Berk BC, Vallega G, Muslin AJ, Gordon HM, Canessa M, Alexander RW. Spontaneously hypertensive rat vascular smooth muscle cells in culture exhibit increased growth and Na+/H+ exchange. J Clin Invest. 1989;83:822-829.
8. Davies JE, Ng LL, Ameen M, Syme PD, Aronson JK. Evidence for altered Na+/H+ antiport activity in cultured skeletal muscle cells and vascular smooth muscle cells from the spontaneously hypertensive rat. Clin Sci. 1991;80:509-516. [Medline] [Order article via Infotrieve]
9. Lever AF. Slow pressor mechanisms in hypertension: a role for hypertrophy of resistance vessels? J Hypertens. 1986;4:512-524.
10. Yamori Y, Igawa T, Tagami M, Kanbe T, Nara Y, Kihara M, Horie R. Humoral trophic influences on cardiovascular structural changes in hypertension. Hypertension. 1984;6(suppl III):III-27-III-32.
11.
Scott-Burden T, Resink TJ, Baur U, Burgin M, Buhler FR.
Epidermal growth factor responsiveness in smooth muscle cells
from hypertensive and normotensive rats.
Hypertension. 1989;13:295-304.
12. Scott-Burden T, Resink TJ, Buhler FR. Enhanced growth and growth factor responsiveness of vascular smooth muscle cells from hypertensive rats. J Cardiovasc Pharmacol. 1989;14(suppl 6):S16-S21.
13.
Resink TJ, Scott-Burden T, Baur U, Burgin M, Buhler FR.
Enhanced responsiveness to angiotensin II in vascular smooth
muscle cells from spontaneously hypertensive rats is not associated
with alterations in protein kinase C.
Hypertension. 1989;14:293-303.
14. Sardet C, Franchi A, Pouyssegur J. Molecular cloning, primary structure, and expression of the human growth factor-activatable Na+/H+ antiporter. Cell. 1989;56:271-280. [Medline] [Order article via Infotrieve]
15.
Tse C-M, Levine SA, Yun CHC, Montrose MH, Little PJ,
Pouyssegur J, Donowitz M. Cloning and expression of a rabbit
cDNA encoding a serum-activated ethylisopropylamiloride-resistant
epithelial Na+/H+ exchanger isoform
(NHE-2). J Biol Chem. 1993;268:11917-11924.
16.
Tse C-M, Brant SR, Walker S, Pouyssegur J,
Donowitz M. Cloning and sequencing of a rabbit cDNA encoding an
intestinal and kidney-specific Na+/H+
exchanger isoform (NHE-3). J Biol Chem. 1992;267:9340-9346.
17.
Orlowski J, Kandasamy RA, Shull GE.
Molecular cloning of putative members of the Na/H exchanger gene
family. J Biol Chem. 1992;267:9331-9339.
18. Siczkowski M, Davies JE, Ng LL. Na+/H+ antiporter protein in normal Wistar-Kyoto and spontaneously hypertensive rat. J Hypertens. 1994;12:775-781. [Medline] [Order article via Infotrieve]
19.
Sardet C, Counillon L, Franchi A, Pouyssegur J.
Growth factors induce phosphorylation of the
Na+/H+ antiporter, a glycoprotein of 110
kD. Science. 1990;247:723-726.
20.
Yusufi ANK, Szczepanska-Konkel M, Dousa TP. Role
of N-linked oligosaccharides in the transport activity of the
Na+/H+ antiporter in rat renal
brush-border membrane. J Biol Chem. 1988;263:13683-13691.
21.
Okada K, Ishikawa S, Saito T. Enhancement of
intracellular sodium by vasopressin in spontaneously hypertensive
rats. Hypertension. 1993;22:300-305.
22.
Fafournoux P, Noel J, Pouyssegur J. Evidence
that Na+/H+ exchanger isoforms NHE1 and
NHE3 exist as stable dimers in membranes with a high degree of
specificity for homodimers. J Biol Chem. 1994;269:2589-2596.
23.
Sardet C, Fafournoux P, Pouyssegur J.
-Thrombin, epidermal growth factor, and okadaic acid activate
the Na+/H+ exchanger, NHE-1, by
phosphorylating a set of common sites. J Biol Chem. 1991;266:19166-19171.
24.
Lifton RP, Hunt SC, Williams RR, Pouyssegur J, Lalouel
JM. Exclusion of the Na+/H+
antiporter as a candidate gene in human essential hypertension.
Hypertension. 1991;17:8-14.
25.
Bukoski RD, DeWan P, Bo J. Mechanism of the
enhanced epidermal growth factorinduced growth response of
genetically hypertensive vascular myocytes.
Circ Res. 1991;69:757-764.
26.
Grinstein S, Woodside M, Sardet C, Pouyssegur J, Rotin
D. Activation of the Na+/H+ antiporter
during cell volume regulation. J Biol Chem. 1992;267:23823-23828.
27. Rao GN, Sardet C, Pouyssegur J, Berk BC. Phosphorylation of Na+-H+ antiporter is not stimulated by phorbol ester and acidification in granulocytic HL-60 cells. Am J Physiol. 1993;264: C1278-C1284.
28.
Wakabayashi S, Bertrand B, Shigekawa M,
Fafournoux P, Pouyssegur J. Growth factor activation and
`H+-sensing' of the
Na+/H+
exchanger isoform 1 (NHE1). J Biol Chem. 1994;269:5583-5588.
29.
Bertrand B, Wakabayashi S, Ikeda T, Pouyssegur J,
Shigekawa M. The Na+/H+ exchanger
isoform 1 (NHE1) is a novel member of the calmodulin-binding proteins:
identification and characterization of calmodulin-binding
sites. J Biol Chem. 1994;269:13703-13709.
30.
Buchholz RA, Dundore RL, Cumiskey WR, Harris AL, Silver
PJ. Protein kinase inhibitors and blood pressure control in
spontaneously hypertensive rats.
Hypertension. 1991;17:91-100.
31. Bruschi G, Bruschi ME, Capelli P, Regolisti G, Borghetti A. Increased sensitivity to protein kinase C activation in aortas of spontaneously hypertensive rats. J Hypertens. 1988;6(suppl 4): S248-S251.
32.
Little PJ, Weissberg PL, Cragoe EJ, Bobik A.
Dependence of Na+/H+ antiport
activation in cultured rat aortic smooth muscle on calmodulin, calcium
and ATP. J Biol Chem. 1988;263:16780-16786.
33. Fliegel L, Walsh MP, Singh D, Wong C, Barr A. Phosphorylation of the C-terminal domain of the Na+/H+ exchanger by Ca2+/calmodulin-dependent protein kinase II. Biochem J. 1992;282:139-145.
34.
Erne P, Hermsmeyer K. Intracellular vascular
muscle Ca2+ modulation in genetic
hypertension. Hypertension. 1989;14:145-151.
This article has been cited by other articles:
![]() |
C. D. Garciarena, C. I. Caldiz, E. L. Portiansky, G. E. Chiappe de Cingolani, and I. L. Ennis Chronic NHE-1 blockade induces an antiapoptotic effect in the hypertrophied heart J Appl Physiol, April 1, 2009; 106(4): 1325 - 1331. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Sandmann, M. Yu, E. Kaschina, A. Blume, E. Bouzinova, C. Aalkjaer, and T. Unger Differential effects of angiotensin AT1 and AT2 receptors on the expression, translation and function of the Na+-H+ exchanger and Na+-HCO3- symporter in the rat heart after myocardial infarction J. Am. Coll. Cardiol., June 15, 2001; 37(8): 2154 - 2165. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. E. Cingolani Na+/H+ exchange hyperactivity and myocardial hypertrophy: Are they linked phenomena? Cardiovasc Res, December 1, 1999; 44(3): 462 - 467. [Full Text] [PDF] |
||||
![]() |
A. N. Moor and L. Fliegel Protein Kinase-mediated Regulation of the Na+/H+ Exchanger in the Rat Myocardium by Mitogen-activated Protein Kinase-dependent Pathways J. Biol. Chem., August 13, 1999; 274(33): 22985 - 22992. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Takahashi, J.-i. Abe, B. Gallis, R. Aebersold, D. J. Spring, E. G. Krebs, and B. C. Berk p90RSK Is a Serum-stimulated Na+/H+ Exchanger Isoform-1 Kinase. REGULATORY PHOSPHORYLATION OF SERINE 703 OF Na+/H+ EXCHANGER ISOFORM-1 J. Biol. Chem., July 16, 1999; 274(29): 20206 - 20214. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. N. Orlov, N. C. Adragna, V. A. Adarichev, and P. Hamet Genetic and biochemical determinants of abnormal monovalent ion transport in primary hypertension Am J Physiol Cell Physiol, March 1, 1999; 276(3): C511 - C536. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Kusuhara, E. Takahashi, T. E. Peterson, J.-i. Abe, M. Ishida, J. Han, R. Ulevitch, and B. C. Berk p38 Kinase Is a Negative Regulator of Angiotensin II Signal Transduction in Vascular Smooth Muscle Cells : Effects on Na+/H+ Exchange and ERK1/2 Circ. Res., October 19, 1998; 83(8): 824 - 831. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. I. Kourie Interaction of reactive oxygen species with ion transport mechanisms Am J Physiol Cell Physiol, July 1, 1998; 275(1): C1 - C24. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Takahashi, J.-i. Abe, and B. C. Berk Angiotensin II Stimulates p90rsk in Vascular Smooth Muscle Cells : A Potential Na+-H+ Exchanger Kinase Circ. Res., August 19, 1997; 81(2): 268 - 273. [Abstract] [Full Text] |
||||
![]() |
M. P. Kelly, P. A. Quinn, J. E. Davies, and L. L. Ng Activity and Expression of Na+-H+ Exchanger Isoforms 1 and 3 in Kidney Proximal Tubules of Hypertensive Rats Circ. Res., June 19, 1997; 80(6): 853 - 860. [Abstract] [Full Text] |
||||
![]() |
V. N. Phan, M. Kusuhara, P. A. Lucchesi, and B. C. Berk A 90-kD Na+-H+ Exchanger Kinase Has Increased Activity in Spontaneously Hypertensive Rat Vascular Smooth Muscle Cells Hypertension, June 1, 1997; 29(6): 1265 - 1272. [Abstract] [Full Text] |
||||
![]() |
P. A. Lucchesi, J. M. Bell, L. S. Willis, K. L. Byron, M. A. Corson, and B. C. Berk Ca2+-Dependent Mitogen-Activated Protein Kinase Activation in Spontaneously Hypertensive Rat Vascular Smooth Muscle Defines a Hypertensive Signal Transduction Phenotype Circ. Res., June 1, 1996; 78(6): 962 - 970. [Abstract] [Full Text] |
||||
![]() |
M. Siczkowski and L. L. Ng Phorbol Ester Activation of the Rat Vascular Myocyte Na+-H+ Exchanger Isoform 1 Hypertension, April 1, 1996; 27(4): 859 - 866. [Abstract] [Full Text] |
||||
![]() |
S. Lehoux, J.-i. Abe, J. A. Florian, and B. C. Berk 14-3-3 Binding to Na+/H+ Exchanger Isoform-1 Is Associated with Serum-dependent Activation of Na+/H+ Exchange J. Biol. Chem., May 4, 2001; 276(19): 15794 - 15800. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Circulation Research Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 1995 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |